Bendell JC et al. CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210). Gastrointestinal Cancers Symposium 2021;Abstract TPS449.
Carrizosa DR et al. CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions. ASCO 2022;Abstract 3006.
Cho BC et al. Phase 1/2 TRIDENT-1 study of repotrectinib in patients with ROS1+ or NTRK+ advanced solid tumors. WCLC 2020;Abstract 3255.
Denlinger CS et al. Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs 2021;39(6):1604-12. Abstract
Drilon A et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Eng J Med 2020;383(9):813-24. Abstract
Dy GK et al. Long-term outcomes with sotorasib in pretreated KRASp.g12C mutated NSCLC: 2-year analysis of CodeBreaK100. AACR 2022;Abstract CT008.
Dziadziuszuko R et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J Clin Oncol 2021;39(11):1253-63. Abstract
Gainor JF et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): A multi-cohort, open-label, phase 1/2 study. Lancet Oncol 2021;22(7):959-69. Abstract
Garon EB et al. TROPION-PanTumor01: Updated results from the NSCLC cohort of the phase 1 study of datopotamab deruxtecan in solid tumors. WCLC 2021;Abstract MA03.02.
Garon EB et al. Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study. ESMO 2021;Abstract LBA49.
Goldman J et al. LIBRETTO-432: A placebo-controlled phase 3 study of adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC. IASLC 2021;Abstract P01.01.
Jänne PA et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med 2022;[Online ahead of print]. Abstract
Johnson ML et al. A phase 2 study of datopotamab deruxtecan (Dato-DXd) in advanced NSCLC with actionable genomic alterations (TROPION-Lung05). WCLC 2021;Abstract P47.05.
Krebs MG et al. Amivantamab in NSCLC patients with MET exon 14 skipping mutation: Updated results from the CRYSALIS study. ASCO 2022;Abstract 9008.
Le X et al. Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: Outcomes in patient subgroups from the VISION study with relevance for clinical practice. Clin Cancer Res 2022;28(6):1117-26. Abstract
Li BT et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2022;386(3):241-51. Abstract
Lietman CD et al. More to the RAS story: KRASG12C inhibition, resistance mechanisms, and moving beyond KRASG12C. ASCO Educational Book 2022;24:1-3. Abstract
Johnson ML et al. Durvalumab +/- tremelimumab + chemotherapy as first-line treatment for mNSCLC: Results from the phase 3 POSEIDON study. WCLC 2021;Abstract PL02.01.
Peters S et al. Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC for the blood first assay screening trail (BFAST). ASCO 2022;Abstract LBA9023.
Peters S et al. Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. ASCO 2022;Abstract 9024.
Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 2022;40(6):611-25. Abstract
Wang J et al. Phase I study of JNJ-74699157 in patients with advanced solid tumors harboring the KRAS G12C mutation. Oncologist 2022;[Online ahead of print]. Abstract
Wolf J et al. Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study. ASCO 2021;Abstract 9020.